Opinion|Videos|May 30, 2024
Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes
Author(s)Anjali Tiku Owens, MD
Anjali Tiku Owens, MD, examines mavacamten, the pioneering cardio myosin inhibitor (CMI) approved for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), which is exclusively accessible through the restricted Risk Evaluation and Mitigation Strategy (REMS) program; the KOL delves into the objectives of this program and how it strives to enhance medication safety and optimize patient outcomes.
Advertisement
Episodes in this series
- Mavacamten is the first approved CMI for oHCM and is only available through the restricted Risk Evaluation and Mitigation Strategy (REMS) program. What is the purpose of this program, and how does it aim to improve medication safety and patient outcomes?
- How does your institution/clinic handle the execution of the REMS program for mavacamen, how do you get certified, what are the institutional protocols?
- What is needed from the patient?
REMS program patient
Advertisement
Related to this article
A recent retrospective analysis presented at HFSA 2026 has demonstrated the association between GLP-1 agonists, weight reduction, and PA pressures.
A new analysis of the SEQUOIA-HCM trial, presented at HFSA 2026, demonstrates aficamten’s association with improvements to an understudied aspect of the condition.
A recent network meta-analysis presented at HFSA 2026 displays finerenone’s favorable safety profile and comparatively greater reduction of acute kidney injury risk.
A new analysis of the phase 3 ATTRibute-CM study, presented at HFSA 2026, may indicate a connection between the number of hospitalizations and mortality risk.
Jennifer Hsiao, MD, discusses HS treatment expectations, biologic selection, oral JAK inhibitors, and comorbidity screening.
Phase 3 extension shows oral denifanstat sustains acne lesion reductions through 52 weeks, with 57% IGA success and 77% fewer inflammatory lesions.
Raj Chovatiya, MD, PhD, discusses biologic choice in atopic dermatitis, pipeline strategies, and remibrutinib’s approval for symptomatic dermographism.
Catch up on HCPLive’s first-half Fall Clinical 2026 coverage, including new psoriasis and atopic dermatitis data and expert insights on HS and vitiligo.
Advertisement
Advertisement
Trending on HCPLive
1
GLP-1 Initiation in Heart Failure Reduces Pulmonary Artery Pressure, Hospitalizations
2
Finerenone Outperforms Spironolactone, Eplerenone in HFpEF, HFmrEF Renal Outcomes
3
Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism
4
Hidradenitis Suppurativa Care: Expectations, Comorbidities, and Wound Care
5